ty - jour t1 - 治疗药物监测使用唾液作为矩阵：线唑胺的机会，但麦克西六唑胺的挑战 - 欧洲呼吸杂志jo - 欧元reshir j do - 10.1183 / 13993003/15是 - 5 sp - 1901903 au -van den Elsen, Simone H.J. AU - Akkerman, Onno W. AU - Jongedijk, Erwin M. AU - Wessels, Mireille AU - Ghimire, Samiksha AU - van der Werf, Tjip S. AU - Touw, Daan J. AU - Bolhuis, Mathieu S. AU - Alffenaar, Jan-Willem C. Y1 - 2020/05/01 UR - //www.qdcxjkg.com/content/55/5/1901903.abstract N2 - The World Health Organization (WHO) has listed moxifloxacin and linezolid among the preferred “group A” drugs in the treatment of multidrug-resistant (MDR)-tuberculosis (TB) [1]. Therapeutic drug monitoring (TDM) could potentially optimise MDR-TB therapy, since moxifloxacin and linezolid show large pharmacokinetic variability [1–4]. TDM of moxifloxacin focuses on identifying patients with low drug exposure who are at risk of treatment failure and acquired fluoroquinolone resistance [5, 6]. Alternatively, TDM of linezolid strives to reduce toxicity while ensuring an adequate drug exposure because of its narrow therapeutic index [1, 3, 7].Therapeutic drug monitoring using saliva as matrix is a suitable alternative for serum therapeutic drug monitoring of linezolid, but not for moxifloxacin due to a high variability in saliva-plasma ratios http://bit.ly/2NIYdz7 ER -